Hey, cut Tercica some slack -- it's feeling a bit hormonal. The company's drug therapies focus on the treatment of growth disorders. The company's lead product Increlex (rhIGF-1) treats children with severe primary insulin-like growth factor deficiency, and its Somatuline Depot (lanreotide) is for the treatment of acromegaly (excess growth hormones) in adults. Cambrex Biosciences manufactures Increlex for the company. Tercica licenses manufacturing and other technology and intellectual property related to the recombinant growth hormone rhIGF-1 from Genentech. Tercica is a subsidiary of European drugmaker Ipsen.